COVID-19NCT05379621
Socio-economic, Meteorological and Environmental Factors Associated With the Incidence of COVID-19
An observational study of COVID-19, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
Trial summary
Socio-demographic factors in relation to the diagnosis of COVID cases are increasingly mentioned in the role of transmission, but unfortunately with a small number of conclusive publications on French data. Read more about this study
- Who is it for?
- Ages 0 to 120 years
- Conditions the study is for
- COVID-19
- What is being tested?
- COVID-19 infection
- How many people
- 28,377 participants
- Where
- 1 siteFrance
- Study dates
- 3 Jan 2021to 14 Feb 2021
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 120 years
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Population of legal age or not residing in the Alpes Maritimes department between 03/01/2021 and 14/02/2021, i.e. 1078729 inhabitants in the Alpes Maritimes, including 342979 in the city of Nice
Who may be able to join
- Any person, adult or not, residing in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
Who cannot join
- Non resident in the Alpes-Maritimes
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Socio-economic, Meteorological and Environmental Factors Associated With the Incidence of COVID-19 in the Alpes-Maritimes and the City of Nice
Socio-demographic factors in relation to the diagnosis of COVID cases are increasingly mentioned in the role of transmission, but unfortunately with a small number of conclusive publications on French data. Our objective is to analyse the distribution of cases according to these factors and their possible role during the first 6 weeks of 2021 when the Alpes Maritimes was the department with the highest incidence rate. The collaboration between ARS06 and the Public Health Department in the field of COVID-19 has made it possible to have a departmental bulletin for monitoring the evolution of the epidemic (incidence, screening, hospitalisation). Knowledge of the socio-demographic, meteorological and environmental factors associated with the transmission of SARS-CoV2 would make it possible to reflect on how to act on these factors and to implement a public health policy.
- Conditions
- COVID-19
- Being tested
- COVID-19 infection
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
COVID-19 infectionOther
All persons of legal age or not resident in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
What is being measured
The primary outcome is the main question the study is designed to answer.
Weekly incidence rate of COVID-19 in the Alpes-Maritimes during the study period.
Weekly incidence rate in the Alpes Maritimes according to the age group, by district of Nice and town
Measured: Between 03/01/2021 and 14/02/2021
Secondary outcomes (2)
Weekly incidence rate of COVID-19 in the Alpes-Maritimes during the study period according to participants' social and economic factors
Weekly incidence rate by social disadvantage index and others socioeconomic indicators by Census block of Nice, correlation analyses
Measured: Between 03/01/2021 and 14/02/2021
Weekly incidence rate of COVID-19 in the Alpes-Maritimes during the study period according to climatic factors
Correlation of incidence rates with temperature, humidity, concentrations in air pollutants (fine particles, nitrogen oxides)
Measured: Between 03/01/2021 and 14/02/2021
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 May 2022
- Study start3 Jan 2021
- Primary completion14 Feb 2021
- Study completion14 Feb 2021
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for COVID-19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
- Enrolment
- 28,377 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Universitaire de Nice
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05379621
- Sponsor's protocol ID
- 22DSP01
- Status last verified
- May 2022
- First submitted
- 16 May 2022
- Last updated
- 18 May 2022
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Marine Barjoan E, Prouvost-Keller B, Chaarana A, Festraets J, Geloen C, Legueult K, Pradier C. Spatial distribution of SARS-CoV-2 incidence, social inequality, housing conditions, and density in South-Eastern France: keys for future epidemics. Front Public Health. 2024 Dec 6;12:1422112. doi: 10.3389/fpubh.2024.1422112. eCollection 2024.
PubMed 39712297Marine Barjoan E, Chaarana A, Festraets J, Geloen C, Prouvost-Keller B, Legueult K, Pradier C. Impact of social and demographic factors on the spread of the SARS-CoV-2 epidemic in the town of Nice. BMC Public Health. 2023 Jun 6;23(1):1098. doi: 10.1186/s12889-023-15917-z.
PubMed 37280635
Study at a glance
From the registry record, last updated by the sponsor on 18 May 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Socio-economic, Meteorological and Environmental Factors Associated With the Incidence of COVID-19 in the Alpes-Maritimes and the City of Nice
- ClinicalTrials.gov ID
- NCT05379621
- Acronym / sponsor ID
- 22DSP01
- Conditions
- COVID-19
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 28,377 participants (actual)
- Lead sponsor
- Centre Hospitalier Universitaire de NiceUniversity, hospital or other
- Study start
- 3 Jan 2021 (actual)
- Primary completion
- 14 Feb 2021 (actual)
- Study completion
- 14 Feb 2021 (actual)
- First posted
- 18 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Socio-demographic factors in relation to the diagnosis of COVID cases are increasingly mentioned in the role of transmission, but unfortunately with a small number of conclusive publications on French data. Our objective is to analyse the distribution of cases according to these factors and their possible role during the first 6 weeks of 2021 when the Alpes Maritimes was the department with the highest incidence rate. The collaboration between ARS06 and the Public Health Department in the field of COVID-19 has made it possible to have a departmental bulletin for monitoring the evolution of the epidemic (incidence, screening, hospitalisation). Knowledge of the socio-demographic, meteorological and environmental factors associated with the transmission of SARS-CoV2 would make it possible to reflect on how to act on these factors and to implement a public health policy.
Study design
- Observational model
- Ecologic or community
- Time perspective
- Cross-sectional
Who may qualify
- Ages
- 0 to 120 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Population of legal age or not residing in the Alpes Maritimes department between 03/01/2021 and 14/02/2021, i.e. 1078729 inhabitants in the Alpes Maritimes, including 342979 in the city of Nice
Key inclusion criteria (1 listed)
- Any person, adult or not, residing in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis.
Key exclusion criteria (1 listed)
- Non resident in the Alpes-Maritimes
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| COVID-19 infectionAll persons of legal age or not resident in the Alpes-Maritimes between 03/01/2021 and 14/02/2021 with a COVID-19 diagnosis. | Other | – |
Primary outcome
Weekly incidence rate of COVID-19 in the Alpes-Maritimes during the study period.
Time frame: Between 03/01/2021 and 14/02/2021
Weekly incidence rate in the Alpes Maritimes according to the age group, by district of Nice and town
2 secondary outcomes
Weekly incidence rate of COVID-19 in the Alpes-Maritimes during the study period according to participants' social and economic factors
Time frame: Between 03/01/2021 and 14/02/2021
Weekly incidence rate of COVID-19 in the Alpes-Maritimes during the study period according to climatic factors
Time frame: Between 03/01/2021 and 14/02/2021
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 May 2022.
- Derived from this study: PubMed 39712297Marine Barjoan E, Prouvost-Keller B, Chaarana A, Festraets J, Geloen C, Legueult K, Pradier C. Spatial distribution of SARS-CoV-2 incidence, social inequality, housing conditions, and density in South-Eastern France: keys for future epidemics. Front Public Health. 2024 Dec 6;12:1422112. doi: 10.3389/fpubh.2024.1422112. eCollection 2024.
- Derived from this study: PubMed 37280635Marine Barjoan E, Chaarana A, Festraets J, Geloen C, Prouvost-Keller B, Legueult K, Pradier C. Impact of social and demographic factors on the spread of the SARS-CoV-2 epidemic in the town of Nice. BMC Public Health. 2023 Jun 6;23(1):1098. doi: 10.1186/s12889-023-15917-z.
Related trials for COVID-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of COVID-19, run by Centre Hospitalier Universitaire de Nice at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 May 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Weekly incidence rate of COVID-19 in the Alpes-Maritimes during the study period. (time frame: Between 03/01/2021 and 14/02/2021). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05379621, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 May 2022.